Bradmer Pharmaceuticals Inc. (TSE:GLX – Get Free Report) has received a consensus rating of “Buy” from the seven analysts that are currently covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and four have given a strong buy recommendation to the company.
A number of brokerages have recently weighed in on GLX. Citigroup upgraded shares of Bradmer Pharmaceuticals to a “hold” rating in a research note on Tuesday, February 24th. Chardan Capital upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, May 4th. Finally, ATB Cormark Capital Markets cut shares of Bradmer Pharmaceuticals from a “strong-buy” rating to a “moderate buy” rating in a report on Thursday, February 5th.
View Our Latest Stock Analysis on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Stock Performance
See Also
- Five stocks we like better than Bradmer Pharmaceuticals
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
